<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="74453">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02136420</url>
  </required_header>
  <id_info>
    <org_study_id>497997</org_study_id>
    <nct_id>NCT02136420</nct_id>
  </id_info>
  <brief_title>Countermeasures to Reduce Sensorimotor Impairment and Space Motion Sickness Resulting From Altered Gravity Levels</brief_title>
  <official_title>Countermeasures to Reduce Sensorimotor Impairment and Space Motion Sickness Resulting From Altered Gravity Levels</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Faisal_Karmali@MEEI.HARVARD.EDU</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Space Biomedical Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Massachusetts Institute of Technology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts Eye and Ear Infirmary</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators will study adaptation of motion perception and manual control in altered
      gravity, including the effects of a drug (promethazine). The investigators will also study
      whether promethazine affects motion perceptual thresholds.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Adaptation to altered gravity has been of concern from the earliest reports of space motion
      sickness, through the Apollo exploration era, and into current planning of exploration
      missions. The proposed research program takes a new approach which could lead to an
      effective, practical and acceptable protocol for preadapting astronauts to space flight. By
      using the gravito-inertial alterations possible with centrifugation in different body
      orientations the investigators will quantify an individual's sensory adaptation capability
      and use it to predict and to minimize the consequences of movement in any other gravity
      environment - eventually including weightlessness. The investigators will also study whether
      a drug (promethazine) affects motion perception and motion sickness.
    </textblock>
  </detailed_description>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    Awaiting scientific review
  </why_stopped>
  <start_date>June 2014</start_date>
  <completion_date type="Anticipated">July 2017</completion_date>
  <primary_completion_date type="Anticipated">July 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Participant</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of recovery of roll tilt perception/manual control errors after exposure to hypergravity</measure>
    <time_frame>1 session</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Yaw perceptual motion threshold, placebo</measure>
    <time_frame>1 session</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Yaw perceptual motion threshold, promethazine</measure>
    <time_frame>1 session</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Roll perceptual motion threshold, placebo</measure>
    <time_frame>1 session</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Roll perceptual motion threshold, promethazine</measure>
    <time_frame>1 session</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Interaural perceptual motion threshold, placebo</measure>
    <time_frame>1 session</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Interaural perceptual motion threshold, promethazine</measure>
    <time_frame>1 session</time_frame>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Vestibular</condition>
  <arm_group>
    <arm_group_label>Training, placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No hypergravity training, placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>subject does test with no hyper gravity training and placebo drug only</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Training, promethazine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>promethazine 25 mg, one time 120 minutes prior to experiment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No hypergravity training, promethazine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>promethazine 25 mg, one time 120 minutes prior to experiment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Perceptual motion threshold testing</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects undergo perceptual motion threshold tests to determine the smallest motion they can reliably sense for yaw rotation, interaural translation and roll tilt. Each subject is tested twice, once with placebo and once with promethazine, separated by &gt;4 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Promethazine</intervention_name>
    <description>Subject receives promethazine</description>
    <arm_group_label>Training, promethazine</arm_group_label>
    <arm_group_label>No hypergravity training, promethazine</arm_group_label>
    <arm_group_label>Perceptual motion threshold testing</arm_group_label>
    <other_name>Phenergan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Hyper gravity training</intervention_name>
    <description>Subject receives hypergravity training before testing</description>
    <arm_group_label>Training, placebo</arm_group_label>
    <arm_group_label>Training, promethazine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Training, placebo</arm_group_label>
    <arm_group_label>No hypergravity training, placebo</arm_group_label>
    <arm_group_label>Perceptual motion threshold testing</arm_group_label>
    <other_name>corn starch</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>No hypergravity training</intervention_name>
    <description>Subjects do not receive normal Earth gravity</description>
    <arm_group_label>No hypergravity training, placebo</arm_group_label>
    <arm_group_label>No hypergravity training, promethazine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects must be in general good health

        Exclusion Criteria:

          -  Anyone who is not generally in good general health does not qualify

          -  Cardiovascular disease

          -  Severe diabetes

          -  Respiratory condition (e.g. asthma or emphysema)

          -  Narrow angle glaucoma

          -  Prostatic hypertrophy

          -  Gastrointestinal disorders
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Faisal Karmali, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts Eye and Ear Infirmary</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts Eye and Ear Infirmary</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 24, 2017</lastchanged_date>
  <firstreceived_date>April 30, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts Eye and Ear Infirmary</investigator_affiliation>
    <investigator_full_name>Faisal_Karmali@MEEI.HARVARD.EDU</investigator_full_name>
    <investigator_title>Primary Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Motion Sickness</mesh_term>
    <mesh_term>Space Motion Sickness</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Promethazine</mesh_term>
    <mesh_term>Diphenhydramine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
